Raloxifene: the first selective estrogen receptor modulator for postmenopausal osteoporosis
New Drugs and Disease Management
- 8 Downloads
KeywordsBone Mineral Density Postmenopausal Woman Endometrial Cancer Alendronate Raloxifene
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 2.Carlson R. MORE not yet enough for raloxifene and breast cancer prevention. Inpharma 1998 Jun 13; 1141: 13–4Google Scholar
- 3.Raloxifene prescribing information. Eli Lilly and Company. Indianapolis, USA, 1997Google Scholar
- 4.British National Formulary. No. 35. London: The Pharmaceutical Press, 1998 Mar: 334–5Google Scholar
- 5.PDR Generics. 4th ed. Montvale (NJ): Medical Economics, 1998: 71–5Google Scholar
- 7.Gunness M, Prestwood K, Lu Y, et al. Histomorphometric, bone marker, and bone mineral density response to raloxifene HCl and Premarin in postmenopausal women [abstract no. OR4-2]. The Endocrine Society 79th Annual Meeting: 1997 Jun 11–14 Programme: Minneapolis. Bethesda, Maryland: The Endocrine Society Press 1997: 67Google Scholar
- 9.Huster W, Shah A, Cohen F, et al. Effect of raloxifene on the endometrium in healthy postmenopausal women. The North American Menopause Society 8th Annual Meeting; 1997 Sep 4–6; BostonGoogle Scholar
- 11.Scheele W, Symanowski SM, Neale S, et al. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women [abstract no. P#-246]. The Endocrine Society 79th Annual Meeting: 1997 Jun 11–14 Programme: Minneapolis. Bethesda, Maryland: The Endocrine Society Press 1997: 498Google Scholar
- 12.Alendronic acid: effective therapy for postmenopausal osteoporosis. Drugs Ther Perspect 1997 Jul 7; 10(1); 1–5Google Scholar
© Adis International Limited 1998